Company Filing History:
1 out of 517 
1 out of 108 
Years Active: 2018
Title: Mark Duquette: Innovator in Thrombospondin-1 Polypeptides
Introduction
Mark Duquette is an accomplished inventor based in Southborough, MA (US). He is known for his significant contributions to the field of biotechnology, particularly in the development of thrombospondin-1 polypeptides. His innovative work has the potential to impact treatments for various disorders, including cancer.
Latest Patents
Mark Duquette holds a patent for "Thrombospondin-1 polypeptides and methods of using same." This invention features thrombospondin-1 (TSP-1) polypeptides, such as 3TSR-Fc fusion proteins, along with nucleic acid molecules encoding these polypeptides. The patent also includes methods for making and using TSP-1 polypeptides, particularly in treating disorders associated with pathological angiogenesis, such as epithelial ovarian cancer (EOC).
Career Highlights
Throughout his career, Mark Duquette has worked with notable institutions, including Beth Israel Deaconess Medical Center, Inc. and the University of Guelph. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mark has collaborated with esteemed colleagues, including John W. Lawler and James Petrik. These partnerships have further enhanced his research and development efforts in the biotechnology sector.
Conclusion
Mark Duquette's innovative work in thrombospondin-1 polypeptides showcases his dedication to advancing medical science. His contributions have the potential to lead to significant advancements in cancer treatment and beyond.